Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Acute Heart Failure
60%
Empagliflozin
30%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
25%
Placebo
23%
Biological Marker
22%
Loop Diuretic Agent
13%
Pathophysiology
13%
Atrial Fibrillation
12%
Brain Natriuretic Peptide
12%
Albuminuria
11%
Ketone Bodies
11%
Dipeptidyl Peptidase
11%
Metabolic Syndrome X
11%
Angiotensin
11%
Renin
11%
Aldosterone
11%
Digoxin
11%
Amiloride Plus Hydrochlorothiazide
5%
Vasopressin Antagonist
5%
Dyspnea
5%
Diuretic Agent
5%
Creatinine
5%
Medicine and Dentistry
Heart Failure
82%
Acute Decompensated Heart Failure
25%
Biological Marker
22%
Empagliflozin
14%
Placebo
13%
Pathophysiology
13%
Loop Diuretic Agent
11%
Albuminuria
11%
Dipeptidyl Peptidase
11%
Cardiac Tamponade
11%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
11%
Kidney Tubule Function
11%
Renin Angiotensin Aldosterone System
11%
Metabolic Syndrome
11%
Brain Natriuretic Peptide
10%
Amino Terminal Sequence
10%
Kidney Function
8%
Urinary System
8%
Diuresis
5%
Vasopressin Antagonist
5%
Diagnosis
5%
Amiloride Plus Hydrochlorothiazide
5%
Glomerular Filtration Rate
5%
Personalized Medicine
5%
Visual Analog Scale
5%
Dyspnea
5%
Diuretic Agent
5%
Creatinine
5%
Keyphrases
Acute Heart Failure
23%
Patients with Heart Failure
17%
Heart Failure
15%
Patients with Chronic Heart Failure
14%
Atrial Fibrillation
12%
Sinus Rhythm
12%
Pathophysiological Pathways
11%
Ketone Bodies
11%
Biomarker Signature
11%
Heart Failure Syndrome
11%
Renal Glucose Reabsorption
11%
Dipeptidyl Peptidase III
11%
Longitudinal Change
11%
Systemic Congestion
11%
Metabolic Syndrome
11%
Congestion
11%
Chronic Heart Failure
11%
Digoxin
11%
Netherlands
11%
Clinical Outcomes
11%
Acetone
5%
